Indications: Uzpruvo is indicated for the treatment of plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis (PsA) and Crohn's disease. Dosage: Uzpruvo is intended for use under the guidance and supervision of physicians experienced in the diagnosis and treatment of conditions for which Uzpruvo is indicated.

Uzpruvo® is an ustekinumab biosimilar from STADA approved for the treatment of: • Moderate to severe Crohn’s disease in adults • Moderate to severe plaque psoriasis and active psoriatic arthritis in adults

Uzpruvo, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1).

2023年11月10日 · Uzpruvo, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

2024年10月30日 · Uzpruvo is intended for use under the guidance and supervision of physicians experienced in the diagnosis and treatment of conditions for which Uzpruvo is indicated. Posology . Uzpruvo is only available as 45 mg and 90 mg solution for injection in pre- filled syringe for subcutaneous use.

PFS, pre-filled syringe; Q8W, every 8 weeks; Q12W, every 12 weeks; SC, subcutaneous *The approved ustekinumab treatment regimen for patients with Crohn's disease is initiation with a single intravenous dose based on body weight. Uzpruvo ® is available in pre-filled syringes for subcutaneous use

2024年7月22日 · 总体而言，Uzpruvo是STADA在欧洲供应的第7种生物仿制药，该德国集团还在骨骼健康、肾脏病学、肿瘤学和眼科治疗领域提供生物仿制药，以及肾脏病学和神经病学领域的差异化专科疗法。

Uzpruvo ® for your Dermatology / Rheumatology patients Introducing Uzpruvo ® : The New Ustekinumab Biosimilar Uzpruvo ® is currently not approved for the ulcerative colitis indication (since the originator still has exclusivity for this indication)

Uzpruvo ® pre-filled syringe (This video is applicable for both 45 mg and 90 mg pre-filled syringe)

Uzpruvo® is an ustekinumab biosimilar from STADA approved for the treatment of: Plaque psoriasis: Adults with moderate to severe plaque psoriasis who failed to